Preclinical evaluation of antitumor activity and toxicity of TROP2-specific CAR-T cells for treatment of triple-negative breast cancer
These data indicate that while CAR-T therapy targeting TROP2 possesses potent antitumor activity against TNBC cell lines and PDX, its potential side effects could be lethal due to TROP2 expression in vital organs such as the lung. Using an "AND"-logic gated CAR is a viable solution to overcome its in vivo toxicity. Our study lays the groundwork for future development of TROP2 CAR-T cell therapy for TNBC.
Authors
- Wanni Xu
- Yang Xu (ORCID: https://orcid.org/0000-0003-1468-2703)
- Ziwei Liang (ORCID: https://orcid.org/0009-0005-5540-4904)
- Fei Wu
- Huizi Wu (ORCID: https://orcid.org/0000-0003-3033-707X)
- Wenzhou Wang (ORCID: https://orcid.org/0009-0003-2994-9308)
- Y. Chen (ORCID: https://orcid.org/0009-0009-7399-5786)
- Shuqun Zhang (ORCID: https://orcid.org/0000-0003-2959-6461)
- Yiwei Jia (ORCID: https://orcid.org/0000-0001-5089-3941)
- Lu Zhang (ORCID: https://orcid.org/0000-0003-2027-9531)
- Li‐Xu Yan (ORCID: https://orcid.org/0000-0002-5584-4265)
- Shiyu Sun (ORCID: https://orcid.org/0000-0003-2836-9435)
- Xiaojia Wang
- Zhang Nian
- Xingcong Ma
Institutions
- Southern University of Science and Technology (CN)
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
- Xijing Hospital (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1136/jitc-2025-012442
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China
- Shenzhen Fundamental Research Program
- Wu Jieping Medical Foundation